178.30
-7.33(-3.95%)
Currency In USD
| Previous Close | 185.63 |
| Open | 185.42 |
| Day High | 186.32 |
| Day Low | 177.05 |
| 52-Week High | 190.2 |
| 52-Week Low | 110.04 |
| Volume | 1.56M |
| Average Volume | 1.96M |
| Market Cap | 26.16B |
| PE | 16.24 |
| EPS | 10.98 |
| Moving Average 50 Days | 172.15 |
| Moving Average 200 Days | 142.64 |
| Change | -7.33 |
If you invested $1000 in Biogen Inc. (BIIB) 10 years ago, it would be worth $635.49 as of January 14, 2026 at a share price of $178.3. Whereas If you bought $1000 worth of Biogen Inc. (BIIB) shares 5 years ago, it would be worth $636.13 as of January 14, 2026 at a share price of $178.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
GlobeNewswire Inc.
Jan 12, 2026 4:05 PM GMT
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
GlobeNewswire Inc.
Jan 06, 2026 1:00 AM GMT
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
GlobeNewswire Inc.
Dec 22, 2025 4:20 PM GMT
Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained previously lost function and strength, someth